mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Emerging microbes & infections - 11(2022), 1 vom: 23. Dez., Seite 1550-1553 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Haomeng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 08.06.2022 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/22221751.2022.2081616 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341273023 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341273023 | ||
| 003 | DE-627 | ||
| 005 | 20231227130810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2022.2081616 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM341273023 | ||
| 035 | |a (NLM)35604772 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Haomeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Beta | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a mRNA | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Chen, Zhao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhenghua |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Zhihong |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jinbo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Airu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Chenlong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guowei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuehu |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Liqiao |e verfasserin |4 aut | |
| 700 | 1 | |a Sui, Xiuwen |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Junqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xiuyu |e verfasserin |4 aut | |
| 700 | 1 | |a Piao, Jinhua |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Juhong |e verfasserin |4 aut | |
| 700 | 1 | |a Shan, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Zhiming |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jincun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Tao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g 11(2022), 1 vom: 23. Dez., Seite 1550-1553 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:1 |g day:23 |g month:12 |g pages:1550-1553 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2022.2081616 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 1 |b 23 |c 12 |h 1550-1553 | ||